Fundamentals of pulmonary drug delivery.

  title={Fundamentals of pulmonary drug delivery.},
  author={David Alexander Groneberg and C Witt and U Wagner and Kian Fan Chung and Axel Fischer},
  journal={Respiratory medicine},
  volume={97 4},
Aerosol administration of peptide-based drugs plays an important role in the treatment of pulmonary and systemic diseases and the unique cellular properties of airway epithelium offers a great potential to deliver new compounds. As the relative contributions from the large airways to the alveolar space are important to the local and systemic availability, the sites and mechanism of uptake and transport of different target compounds have to be characterized. Among the different respiratory cells… 

Figures and Tables from this paper

Novel strategies of aerosolic pharmacotherapy.

  • D. GronebergH. PaulT. Welte
  • Biology
    Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie
  • 2006

Surfactants: their critical role in enhancing drug delivery to the lungs.

The main use attributed to surfactants in pulmonary drug delivery is as absorption enhancers by mechanisms of action not yet fully understood, and they have been used to improve the delivery of inhaled drugs in various additional strategies discussed herein.


Pulmonary diseases may be treated effectively and efficiently using inhalable therapeutic agents loaded nanoparticles allowing for nanoparticles to be safely utilized as therapeutic agents for site-specific drug delivery.

Novel drug delivery systems and significance in respiratory diseases

  • B. MishraJuhi Singh
  • Biology, Medicine
    Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems
  • 2020

Nanomedicine in pulmonary delivery

This review focuses on the current status and explores the potential of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention to their pharmaceutical aspects.

Pulmonary Delivery of Biological Drugs

The characteristics of biological drugs and the barriers to pulmonary drug delivery are assessed, together with the main challenges in the formulation and inhalation devices are discussed and the possible strategies that can be applied to address these challenges are discussed.

Phospholipids in pulmonary drug delivery

This review focuses on the formulations containing phospholipids or PEGylated phospholIPids, such as micelles, liposomes, lipid micro-/nanoparticles, large porous particles, solid dispersions, and microparticle suspensions.

Passive lung-targeted drug delivery systems via intravenous administration

The development, evaluation and application of lung-targeted drug delivery systems via intravenous administration for the treatment of lung diseases reported in the past decades are reviewed.

Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport.

Based on the recent progress in understanding the structural requirements for substrate binding and transport, PEPT2 becomes a target for a rational drug design that may lead to a new generation of respiratory drugs and prodrugs that can be delivered to the airways via the peptide transporter.

Nanocarriers for respiratory diseases treatment: recent advances and current challenges.

The recognition of receptor expressed only at lung level may facilitate drug targeting to this organ and it should improve the therapeutic efficacy of nanocarrier-based treatments for respiratory diseases.



Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung

Findings provide evidence for the expression and function of the peptide transporter PEPT2 in the normal and cystic fibrosis human respiratory tract and suggest that PepT2 is likely to play a role in the transport of pulmonary peptides and peptidomimetics.

Pulmonary cell biology.

  • R. MasonR. Crystal
  • Medicine, Biology
    American journal of respiratory and critical care medicine
  • 1998
The purpose of this review is to relate developments in lung cell biology to the understanding and treatment of pulmonary diseases and to focus on surfactant and alveolar type II cell biology and on the molecular basis of a 1-antitrypsin deficiency.

Deposition Patterns of Aerosolized Drugs Within Human Lungs: Effects of Ventilatory Parameters

The model has implications with regard to aerosol therapy, indicating that the efficacies of inhaled pharmacological drugs in the prophylaxis and treatment of airway diseases can be improved by regulating breathing profiles to deposit particles selectively at prescribed sites within the lung.

The Rationale for Aerosolized Antibiotics

In order for an antimicrobial agent to be effective, it must fulfill two requirements. First, the agent must reach the site of infection and remain in the vicinity for an adequate length of time.

Behavior of Hygroscopic Pharmaceutical Aerosols and the Influence of Hydrophobic Additives

An approach to achieving control of hygroscopic growth of aerosol particles is discussed, conceivable that an aerosol particle could be fabricated of known initial size and density, and by implication, deposition characteristics, and this might be induced to follow specific growth kinetics to enhance deposition in a particular region of the lung.

Clinical evaluation of a simple demand inhalation MDI aerosol delivery device.

In a group of nine patients with stable asthma, inhalation of a bronchodilator aerosol using the breath-actuated device (Aerochamber) achieved effective bronchidilation similar to an optimally administered MDI.

Aerosol delivery systems for bronchial asthma.

From the array of available devices, doctors will increasingly be able to select the most comfortable and convenient for the patient-and therefore most likely to encourage good compliance.

Macrophages and polymorphonuclear neutrophils in lung defense and injury.

Alveolar macrophages are part of the regulatory mechanisms of PMN mobility and adherence that appears to be crucial in the initiation of some inflammatory reactions, and this supports a central role for alveolarmacrophages in the regulation of PMn traffic in the lungs.

Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension

This strategy was extended by nebulizing prostacyclin and a stable analog, iloprost, in patients with severe pulmonary hypertension, and achieved selective pulmonary vasodilatation with a concomitant improvement of ventilation-perfusion matching in mechanically ventilated patients with the adult respiratory distress syndrome.